Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos
E
E
Jäger
D
D
Katus
H A
HA
Frey
N
N
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D009202:Cardiomyopathies / Q000139:chemically induced*; D000075202:Contraindications; D004452:Echocardiography; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000009:adverse effects*; D012720:Severity of Illness Index; D000077210:Sunitinib; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib
J Clin Oncol. 2005 Oct 1;23(28):7135-42
16192597
J Clin Oncol. 2006 Jan 1;24(1):16-24
16330672
Clin Res Cardiol. 2006 Mar;95(3):154-61
16598528
Nat Med. 2006 Aug;12(8):908-16
16862153